Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Bevacizumab has been found to prolong progression free survival in first line, and more
recently, in second line treatment for platinum sensitive ovarian cancer patients who had not
received prior treatment with bevacizumab.
Recently reported data suggest that patients with colon cancer who receive bevacizumab in
more than one line of therapy (beyond progression) have better results. In ovarian cancer,
the role of bevacizumab administered in both first and second-line therapies needs to be
defined.
This study aims to evaluate whether administering bevacizumab in combination with
chemotherapy in second-line therapy to patients with recurrent ovarian cancer who have
received first-line bevacizumab will be more effective than chemotherapy alone.
Phase:
Phase 3
Details
Lead Sponsor:
National Cancer Institute, Naples
Collaborator:
Mario Negri Institute for Pharmacological Research